Comparative clinical evaluation of endothelin receptor antagonists in pulmonary arterial hypertension using a multi-criteria decision analysis framework
Zihan Cao, Long Meng, Yunlong Li, Mi Zhou, Huiming Jiang, Jun Wang, Yi Tao, Feng Qiu · 2026
Read Comparative clinical evaluation of endothelin receptor antagonists in pulmonary arterial hypertension using a multi-criteria decision analysis framework by Zihan Cao, Long Meng, Yunlong Li, Mi Zhou, Huiming Jiang, Jun Wang, Yi Tao, Feng Qiu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13569528.txt.
Description
Cao and colleagues compared in 2026 the three main endothelin blocker drugs for pulmonary arterial hypertension, using a structured scoring framework built with nineteen experts. The disease raises pressure in the lung arteries. The drugs differ in benefit, side effects, blood-test burden, interactions, and price, which complicates pharmacy and formulary choices in China.
Twelve trials supplied the hard numbers. All three drugs improved walking distance and blood flow measures, with ambrisentan showing the largest walking gains and a trend to fewer drug harms. Yearly drug costs in China ran lowest for bosentan and far highest for macitentan, and the cost per meter of walking gained was lowest for ambrisentan. After weighting all six domains, from safety to access, ambrisentan scored highest overall. The authors offer the framework as a transparent tool for hospital drug decisions.
Catalog record
| CREATOR | Zihan Cao, Long Meng, Yunlong Li, Mi Zhou, Huiming Jiang, Jun Wang, Yi Tao, Feng Qiu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |